Conspectus
The predictable and controllable interaction of small organic or
peptidic molecules with biological substrates is the primary reason
most pharmaceuticals are narrowly decorated carbon frameworks. The
inhibition or activation binding models are measurable and without
side reactions that can cause pathological angst. Yet many diseases,
especially those involving rapid proliferation of cells (i.e., cancer)
or aggregation of peptides (e.g., heart disease, Alzheimer’s
disease) have not yet been cured by inhibition therapeutics. Additionally,
interventional medicine is often required to alleviate such maladies
by physical removal first, followed by molecular-level therapy as
a second stage. Thus, there appears to be a niche for more aggressive
therapeutics that may employ harsher chemical processes to realize
clinical efficacy, albeit without causing catastrophic side effects.
Molecules that may be considered for this challenge are not typically
biomimetic, nor do they fit the traditional pharmaceutical paradigm.
They may have unusual modes of action or undesired reactivity that
can be lethal if not controlled. These are the outliers; potential
pharmacophores that biology does not know how to manage or adapt to.
This is why they may be an intriguing class of agents that needs continuous
development.
In this Account, we connect the under-developed
enediyne family
of compounds and our metalloenediyne derivatives to existing radical-based
therapeutics such as bleomycin and doxorubicin to illustrate that
controlled diradical reactivity, although an outlier mechanism, has
a place in the therapeutic portfolio. This is self-evident in that
of the 11 natural product enediynes known, 2 have clinical impact,
a strong ratio. We expand on the chemical diversity of potential enediyne
constructs and focus on the accessible trigger mechanisms to activate
diradical formation as a method to control toxicity. Moreover, we
further illustrate how electromagnetic fields can be employed to activate
both molecular and larger nanomaterial constructs that carry highly
concentrated payloads of reactive reagent. Finally, we describe how
controlled diradical reactivity can reach beyond traditional therapeutic
targets such as DNA, to peptide aggregates found in blood clots, neural
fibrils, and membrane scaffolds. It is our belief that cleverly constructed
frameworks with well-designed and controlled activation/reaction schemes
can lead to novel therapeutics that can challenge evolving viral and
bacterial invaders. From this evangelical perspective, our hope is
that the conceptual framework, if not the specific designs in this
Account, stimulate the readership to develop out-of-the-box therapeutic
designs that may combat resistant disease targets.